Hormonal
Salsalate, a non-acetylated salicylate, lowers blood glucose and triglycerides in type 2 diabetes by activating AMPK and inhibiting NF-κB, but its effect on cardiovascular plaque progression is unclear.
Salsalate, a form of salicylate, can lower blood sugar and triglycerides in people with type 2 diabetes by activating AMPK, a key metabolic sensor. While it shows promise for glycemic control, its effect on preventing heart disease (plaque progression) is not yet clear. It is not a standard treatment but may be considered in specific cases.
More recent proof-of-concept studies showed salsalate, a prodrug dimer of salicylate, lowered fasting glucose and triglycerides, increased adiponectin, and improved glucose utilization during euglycemic-hyperinsulinemic clamps in T2D and obese nondiabetic persons.
Why this rating
Multiple randomized trials show glycemic benefit, but cardiovascular outcomes are mixed or inconclusive.
Source
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Allison B. Goldfine et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci88884
More from this paper
- Statins reduce cardiovascular events and inflammatory markers (CRP) but may increase the risk of new-onset diabetes, indicating a trade-off between cardiovascular protection and glycemic control.Strong
- Obesity-related sub-acute chronic inflammation acts as a pathologic mediator for both type 2 diabetes and atherosclerotic cardiovascular disease, with inflammatory markers like CRP predicting risk independently of weight.Good
- IL-1β antagonists (e.g., anakinra, gevokizumab) improve glycemia and beta-cell function in type 2 diabetes, but their effect on cardiovascular events is still being determined in large trials.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →